Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01648179 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects

A Phase 1 study, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target

NCT01648179 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 24 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01648179, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target

Study Summary

This study is an open-label, randomized, single dose, four period, balanced crossover study to assess in eligible healthy male or female subjects.

Interventions

  • DRUG GSK1322322 (mesylate salt) Powder for Injection
  • DRUG GSK1322322 (freebase) tablets
  • DRUG GSK1322322 (mesylate salt) Powder for Oral Solution
  • DRUG GSK1322322 (freebase) tablets FED

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2012-03
Est. Completion 2012-05
Phase Phase 1

Sponsor

GlaxoSmithKline

1,345 total trials

What the Registry Record Tells You About NCT01648179

The ClinicalTrials.gov registry entry for NCT01648179 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which GSK1322322 (mesylate salt) Powder for Injection is the first listed.

NCT01648179 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01648179 about?

NCT01648179 is a clinical study titled "A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects". This study is an open-label, randomized, single dose, four period, balanced crossover study to assess in eligible healthy male or female subjects.

What is the current status of trial NCT01648179?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2012-03. Estimated completion is 2012-05.

What interventions are being tested in trial NCT01648179?

The interventions under investigation include: GSK1322322 (mesylate salt) Powder for Injection (DRUG), GSK1322322 (freebase) tablets (DRUG), GSK1322322 (mesylate salt) Powder for Oral Solution (DRUG), GSK1322322 (freebase) tablets FED (DRUG).

Who is sponsoring clinical trial NCT01648179?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.